Free Trial
→ The chokepoint supplier behind SpaceX's $1.75 trillion empire (From Behind the Markets) (Ad)tc pixel Free ANAB Stock Alerts

AnaptysBio (ANAB) Competitors

AnaptysBio logo
$69.53 -0.25 (-0.36%)
As of 03:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

ANAB vs. IBRX, QGEN, ACLX, KYMR, and PTGX

Should you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include ImmunityBio (IBRX), Qiagen (QGEN), Arcellx (ACLX), Kymera Therapeutics (KYMR), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does AnaptysBio compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and AnaptysBio (NASDAQ:ANAB) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

AnaptysBio has higher revenue and earnings than ImmunityBio. AnaptysBio is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBio$113.29M68.83-$351.40M-$0.38N/A
AnaptysBio$234.60M8.62-$13.23M-$0.52N/A

In the previous week, ImmunityBio had 30 more articles in the media than AnaptysBio. MarketBeat recorded 37 mentions for ImmunityBio and 7 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.11 beat ImmunityBio's score of 0.04 indicating that AnaptysBio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImmunityBio
0 Very Positive mention(s)
1 Positive mention(s)
35 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
AnaptysBio
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

8.6% of ImmunityBio shares are owned by institutional investors. 69.5% of ImmunityBio shares are owned by insiders. Comparatively, 33.5% of AnaptysBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ImmunityBio has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

AnaptysBio has a net margin of -5.64% compared to ImmunityBio's net margin of -310.18%. ImmunityBio's return on equity of 0.00% beat AnaptysBio's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunityBio-310.18% N/A -81.40%
AnaptysBio -5.64%-1,101.24%-3.59%

ImmunityBio currently has a consensus target price of $14.40, indicating a potential upside of 89.85%. AnaptysBio has a consensus target price of $76.18, indicating a potential upside of 9.57%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities analysts clearly believe ImmunityBio is more favorable than AnaptysBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunityBio
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
AnaptysBio
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

Summary

ImmunityBio beats AnaptysBio on 10 of the 17 factors compared between the two stocks.

How does AnaptysBio compare to Qiagen?

Qiagen (NYSE:QGEN) and AnaptysBio (NASDAQ:ANAB) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Qiagen has a net margin of 20.33% compared to AnaptysBio's net margin of -5.64%. Qiagen's return on equity of 14.56% beat AnaptysBio's return on equity.

Company Net Margins Return on Equity Return on Assets
Qiagen20.33% 14.56% 8.62%
AnaptysBio -5.64%-1,101.24%-3.59%

70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 33.5% of AnaptysBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Qiagen currently has a consensus target price of $47.09, indicating a potential upside of 38.68%. AnaptysBio has a consensus target price of $76.18, indicating a potential upside of 9.57%. Given Qiagen's higher probable upside, equities analysts clearly believe Qiagen is more favorable than AnaptysBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen
0 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.50
AnaptysBio
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

Qiagen has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qiagen$2.09B3.35$424.88M$2.0216.81
AnaptysBio$234.60M8.62-$13.23M-$0.52N/A

In the previous week, Qiagen had 17 more articles in the media than AnaptysBio. MarketBeat recorded 24 mentions for Qiagen and 7 mentions for AnaptysBio. Qiagen's average media sentiment score of 0.18 beat AnaptysBio's score of 0.11 indicating that Qiagen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Qiagen
4 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Neutral
AnaptysBio
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Qiagen has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Summary

Qiagen beats AnaptysBio on 12 of the 17 factors compared between the two stocks.

How does AnaptysBio compare to Arcellx?

AnaptysBio (NASDAQ:ANAB) and Arcellx (NASDAQ:ACLX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

AnaptysBio has a net margin of -5.64% compared to Arcellx's net margin of -1,027.26%. Arcellx's return on equity of -55.42% beat AnaptysBio's return on equity.

Company Net Margins Return on Equity Return on Assets
AnaptysBio-5.64% -1,101.24% -3.59%
Arcellx -1,027.26%-55.42%-36.24%

96.0% of Arcellx shares are held by institutional investors. 33.5% of AnaptysBio shares are held by company insiders. Comparatively, 8.4% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

AnaptysBio currently has a consensus target price of $76.18, indicating a potential upside of 9.57%. Arcellx has a consensus target price of $111.87, indicating a potential downside of 2.78%. Given AnaptysBio's stronger consensus rating and higher probable upside, equities research analysts clearly believe AnaptysBio is more favorable than Arcellx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AnaptysBio
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75
Arcellx
1 Sell rating(s)
16 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.11

AnaptysBio has higher revenue and earnings than Arcellx. AnaptysBio is trading at a lower price-to-earnings ratio than Arcellx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnaptysBio$234.60M8.62-$13.23M-$0.52N/A
Arcellx$22.29M301.95-$228.93M-$4.07N/A

In the previous week, Arcellx had 4 more articles in the media than AnaptysBio. MarketBeat recorded 11 mentions for Arcellx and 7 mentions for AnaptysBio. Arcellx's average media sentiment score of 0.65 beat AnaptysBio's score of 0.11 indicating that Arcellx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AnaptysBio
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcellx
3 Very Positive mention(s)
5 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

AnaptysBio has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.

Summary

AnaptysBio beats Arcellx on 10 of the 17 factors compared between the two stocks.

How does AnaptysBio compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and AnaptysBio (NASDAQ:ANAB) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

AnaptysBio has higher revenue and earnings than Kymera Therapeutics. AnaptysBio is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera Therapeutics$51.48M132.12-$311.35M-$3.57N/A
AnaptysBio$234.60M8.62-$13.23M-$0.52N/A

Kymera Therapeutics presently has a consensus target price of $118.70, indicating a potential upside of 43.57%. AnaptysBio has a consensus target price of $76.18, indicating a potential upside of 9.57%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Kymera Therapeutics is more favorable than AnaptysBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
1 Sell rating(s)
0 Hold rating(s)
20 Buy rating(s)
1 Strong Buy rating(s)
2.95
AnaptysBio
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

In the previous week, Kymera Therapeutics had 19 more articles in the media than AnaptysBio. MarketBeat recorded 26 mentions for Kymera Therapeutics and 7 mentions for AnaptysBio. Kymera Therapeutics' average media sentiment score of 0.38 beat AnaptysBio's score of 0.11 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kymera Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
AnaptysBio
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Kymera Therapeutics has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

AnaptysBio has a net margin of -5.64% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat AnaptysBio's return on equity.

Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics-611.94% -24.71% -22.05%
AnaptysBio -5.64%-1,101.24%-3.59%

Summary

Kymera Therapeutics beats AnaptysBio on 10 of the 15 factors compared between the two stocks.

How does AnaptysBio compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and AnaptysBio (NASDAQ:ANAB) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

AnaptysBio has higher revenue and earnings than Protagonist Therapeutics. AnaptysBio is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$46.02M138.34-$130.15M-$2.05N/A
AnaptysBio$234.60M8.62-$13.23M-$0.52N/A

Protagonist Therapeutics presently has a consensus target price of $108.15, indicating a potential upside of 9.25%. AnaptysBio has a consensus target price of $76.18, indicating a potential upside of 9.57%. Given AnaptysBio's higher possible upside, analysts clearly believe AnaptysBio is more favorable than Protagonist Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagonist Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80
AnaptysBio
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

98.6% of Protagonist Therapeutics shares are held by institutional investors. 4.9% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 33.5% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Protagonist Therapeutics had 4 more articles in the media than AnaptysBio. MarketBeat recorded 11 mentions for Protagonist Therapeutics and 7 mentions for AnaptysBio. Protagonist Therapeutics' average media sentiment score of 1.22 beat AnaptysBio's score of 0.11 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protagonist Therapeutics
7 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AnaptysBio
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Protagonist Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

AnaptysBio has a net margin of -5.64% compared to Protagonist Therapeutics' net margin of -282.83%. Protagonist Therapeutics' return on equity of -19.89% beat AnaptysBio's return on equity.

Company Net Margins Return on Equity Return on Assets
Protagonist Therapeutics-282.83% -19.89% -18.40%
AnaptysBio -5.64%-1,101.24%-3.59%

Summary

Protagonist Therapeutics beats AnaptysBio on 9 of the 16 factors compared between the two stocks.

Get AnaptysBio News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANAB vs. The Competition

Export
MetricAnaptysBioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.01B$3.39B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-132.8838.9029.0628.47
Price / Sales8.62159.23475.7561.65
Price / CashN/A57.8827.6236.52
Price / Book51.897.039.716.67
Net Income-$13.23M$23.62M$3.55B$332.53M
7 Day Performance5.17%3.52%1.65%1.98%
1 Month Performance20.54%7.03%5.54%9.14%
1 Year Performance235.41%66.41%34.16%39.55%

AnaptysBio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANAB
AnaptysBio
2.1724 of 5 stars		$69.53
-0.4%		$76.18
+9.6%		N/A$2.01B$234.60MN/A100
IBRX
ImmunityBio
2.7871 of 5 stars		$6.96
flat		$14.40
+106.9%		N/A$7.16B$113.29MN/A590
QGEN
Qiagen
4.5561 of 5 stars		$33.61
-1.2%		$48.31
+43.8%		N/A$6.93B$2.09B16.675,654
ACLX
Arcellx
2.0054 of 5 stars		$115.07
flat		$111.87
-2.8%		N/A$6.73B$22.29MN/A80
KYMR
Kymera Therapeutics
2.9407 of 5 stars		$81.51
-2.8%		$118.90
+45.9%		N/A$6.65B$39.21MN/A170

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ANAB) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel